Psychological inhibition

Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)

1 month ago talkbio0Tagged Autoimmune, Autoimmune thrombocytopenia, B-cell depletion, ianalumab, Infrequent, Inosine Triphosphate, Novartis, Phase 3, platelet levels, Psychological inhibition, regulatory submissions, Sjögren 's disease, TNFRSF13C protein, human, treatment failure, VAY736

Novartis; ianalumab; VAY736; primary immune thrombocytopenia; ITP; rare disease; Phase 3; time to treatment failure; safe platelet levels; eltrombopag; autoimmune; B-cell depletion; BAFF-R inhibition; Sjögren’s disease; regulatory submissions

Solbinsiran: Eli Lilly’s Promising ANGPTL3 Inhibitor for Lipid Management

5 months ago talkbio0Tagged ANGPTL3, Dyslipidemias, Lipids, Psychological inhibition, RNA, Small Interfering, solbinsiran

ANGPTL3 inhibition, solbinsiran, dyslipidemia, lipid reduction, siRNA therapy

Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

9 months ago talkbio0Tagged disease treatment, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, HSCT-TMA, Improvement, Infrequent, Inhibitor, Lectin, MASP2 protein, human, narsoplimab, Overall Survival, Psychological inhibition

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement